Investigating new ways to target the CB1 receptor for treating various diseases
Official title: In vitro and in vivo characterization of CB1 allosteric modulators
Funded at Upstate Medical University · NIH-10954461 · Data updated 2026-11-12
This study is looking at new ways to help people with drug addiction, pain, and obesity by finding safer treatments that work on a specific part of the brain called the CB1 receptor, so patients can feel better without the unwanted side effects of current medications.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Upstate Medical University NIH-funded |
| Lab location | 1 site (Syracuse, United States) |
| Project start | November 15, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2022 |
| Award (this year) | $159,535 |
| NIH project number | 7K01DA045752-06 |
| Project ID | NIH-10954461 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals suffering from drug dependence, chronic pain, or obesity/metabolic syndrome.
✕Less likely to help
Patients who do not have conditions related to the CB1 receptor may not receive any benefit from this research.
What this research studies
This research focuses on the cannabinoid type-1 (CB1) receptor, which is a potential target for treating conditions like drug addiction, pain, and obesity. The study aims to explore new compounds that can modulate the CB1 receptor's activity without the negative side effects seen in existing medications. By examining how these compounds interact with the receptor and affect its signaling pathways, the research seeks to develop safer and more effective treatments. Patients may benefit from improved therapies that target their specific conditions with fewer adverse effects.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective treatments for conditions like addiction, pain, and metabolic disorders.
How similar studies have gone: While there have been challenges with existing CB1-targeting drugs, the approach of allosteric modulation is relatively novel and has shown promise in preliminary studies.
Where this research is happening
-
Upstate Medical University
Syracuse, United States Active
Researchers
- Principal investigator: Gamage, Thomas F — Upstate Medical University
- Study coordinator: Gamage, Thomas F
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.